|Medtronic Strengthens Commitment to Asia Pacific|
New Asia Pacific Regional Headquarters to Meet Healthcare Demands in the Region
Establish Centre of Excellence with SingHealth to Enhance Patient Care for Diabetes
SINGAPORE - May 31, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, today announced the opening of its new Asia Pacific regional headquarters in Singapore. The new facility, which houses the Asia Pacific Service and Repair Centre of Excellence, will strengthen and support Medtronic operations across 80 locations in Asia Pacific. This will further help Medtronic deliver on the growing demand for medical products and services.
With the opening, Medtronic International Limited signed a Memorandum of Understanding with SingHealth to develop a Centre of Excellence in the treatment of diabetes across Southeast Asia.
"The opening of Medtronic regional headquarters in Singapore marks an important milestone in our growing presence in Asia Pacific. We continue to leverage our regional expertise and partnerships to reach more patients, in more places and through more ways via collaborating with new partners," said Bob White, president, Asia Pacific at Medtronic. "The rising prevalence of diabetes in the region is driving up healthcare costs and adversely impacting the lives of millions of people. There is tremendous opportunity to improve treatments across the diabetes care continuum via meaningful innovation and collaboration. We are excited to work with SingHealth as our strategic partner to explore new approaches in solving challenges associated with diabetes care."
The alliance will pair Medtronic expertise in advanced diabetes management solutions with SingHealth's experience in holistic diabetes care in order to:
"There is an urgent need to tackle the diabetes challenge globally to reduce the burden of the disease. This will require active collaboration between different stakeholders to address the needs of our patients. We see this partnership with Medtronic as an exciting way forward in bringing better diabetes care to our patients, particularly through the adoption of innovative technology," said Dr. Bee Yong Mong, head, SingHealth Duke-NUS Diabetes Centre and senior consultant, Department of Endocrinology, Singapore General Hospital.
"Some of today's most pertinent healthcare challenges such as rising healthcare costs and a rapidly ageing population call for new approaches and models. With its sizeable presence in Singapore, we welcome Medtronic's contributions in this multi-stakeholder effort to transform healthcare," said Ms. Thien Kwee Eng, assistant managing director, Singapore Economic Development Board (EDB). "We believe this will set a strong precedent for industry to participate actively in co-creating new healthcare solutions out of Singapore, which will benefit healthcare in Singapore and the region."
Medtronic is focused on delivering therapy innovation via new products, services and solutions, driving global access to improve standards of care, and creating economic value in healthcare systems to reduce costs. The growing presence of Medtronic in Asia Pacific demonstrates its strong commitment to transform healthcare through strategic partnerships.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.